Skip to main content
. Author manuscript; available in PMC: 2011 Aug 11.
Published in final edited form as: Am J Transplant. 2006 Aug 4;6(10):2409–2417. doi: 10.1111/j.1600-6143.2006.01495.x

Table 5.

Incidence of living donor renal transplant recipients with ACR* at mean follow-up of 493 days

Alemtuzumab induction Historical control p-value
Recipients 205 47
Cumulative recipients with ACR* at
≤1 month** 1.5% (3) 12.8% (6) p < 0.05
≤2 months 1.5% (3) 12.8% (6) p < 0.05
≤3 months 2.0% (4) 12.8% (6) p < 0.05
≤4 months 2.4% (5) 17.0% (8) p < 0.05
≤6 months 2.9% (6) 17.0% (8) p < 0.05
≤12 months 6.8% (14) 17.0% (8) p = 0.047
At mean follow-up of 493 days, cumulative recipients with ACR were 10.7% (22) 21.3% (10) p < 0.05
ACR recipients with >1 ACR episode 45.5% (10) 50.0% (5) –
Weaning attempted 57.0% (118) –
Preweaning ACR incidence 4.3% (9) –
Postweaning ACR incidence 6.3% (13) –
*

All ACR were biopsy proven.